Phase III KEYNOTE-B15: Perioperative Enfortumab Vedotin-ejfv + Pembrolizumab Improves Outcomes in Cisplatin-Eligible Muscle-Invasive Bladder Cancer
Phase III KEYNOTE-B15 data demonstrate significant improvements in event-free survival (EFS), overall survival (OS) and pathologic complete response (pCR) rates compared with standard cisplatin-based perioperative...


